The Rosen Law Firm announces that it is investigating the Board of Directors of Hospira, Inc. (NYSE:HSP) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Hospira to maximize shareholder value before agreeing to be acquired by Pfizer Inc. (NYSE:PFE).

If you would like to join the action, go to http://rosenlegal.com/cases-500.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $90.00 in cash for each share of Hospira they own. The proposed transaction is valued at approximately $17 billion. The investigation relates to whether the proposal is fair to the public shareholders of Hospira and whether Hospira's Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of Hospira and wish to obtain additional information, please visit the website at http://rosenlegal.com/cases-500.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010